The story of Viagra, formerly marketed by copyright, presents a complex case study for investors considering the pharmaceutical arena . While its early success and generation of billions in revenue , the exclusivity lapse has opened the way for alternative medications, substantially diminishing profit potential . This transition raises doubts about